Venetoclax (Venclexta)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:
  • Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
Patients must meet the following criteria for the indications above:
  • Prescribed by an oncologist, AND
  • Patient is at least 18 years of age, AND
  • Medical record documentation confirms diagnosis of CLL with 17p deletion (as detected by an FDA approved test), AND
  • Patient has received at least one prior therapy (Imbruvica is the preferred first-line therapy), AND
  • Patient is not concomitantly using Venclexta with strong CYP3A inhibitors at intiation and during ramp-up phase (patients who have completed the ramp-up phase and are on a steady daily dose of Venclexta: reduce the Venclexta dose by at least 75% when used concomitantly with strong CYP3A inhibitors).
  • Avoid concomitant use of Venclexta with moderate CYP3A inhibitors or P-gp inhibitors with Venclexta (if they must be used with Venclexta, reduce the Venclexta dose by at least 50%)
  • Avoid concomitant use of Venclexta with strong or moderate CYP3A Inducers.
Dosing:
  • Initially 20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg
  • Perform prophylaxis for tumor lysis syndrome
Approval:
  • 1 year

 

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar